Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS4 | Q9NRS4 | 7/20 | 0.50 |
| ▸ | P2RX1 | P51575 | 8/20 | 0.47 |
| ▸ | P2RX4 | Q99571 | 3/20 | 0.47 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.47 |
| ▸ | KCNMA1 | Q12791 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2297569 | 0.94 | TMPRSS4 (0.49) | TMPRSS4P2RX1P2RX4P2RX7KCNMA1 | |
| SCHEMBL2297522 | 0.91 | RAB9A (0.44) | P2RX1NPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL2295353 | 0.91 | RAB9A (0.45) | NPC1RAB9ASMN1; SMN2TP53LMNA | |
| SCHEMBL5291854 | 0.89 | RAB9A (0.41) | TMPRSS4NPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL5288993 | 0.89 | PTGS1 (0.49) | — | |
| SCHEMBL2296222 | 0.89 | RAB9A (0.42) | TMPRSS4P2RX1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2295278 | 0.86 | MEN1 (0.45) | TMPRSS4P2RX1KCNMA1NPC1RAB9A | |
| SCHEMBL2295816 | 0.85 | RAB9A (0.45) | NPC1RAB9ASMN1; SMN2TP53LMNA | |
| SCHEMBL2297464 | 0.84 | RAB9A (0.44) | NPC1RAB9ASMN1; SMN2TP53LMNA | |
| SCHEMBL2295674 | 0.84 | NPC1 (0.56) | NPC1RAB9ASMN1; SMN2TP53LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003806-B2 | Integrin antagonists useful as anticancer agents | OSI Pharmaceuticals, LLC (US) | 2011-08-23 | — | — | US | claimed |
| EP-1828144-A2 | INTEGRIN ANTAGONISTS USEFUL AS ANTICANCER AGENTS | OSI Pharmaceuticals, Inc. (US) | 2007-09-05 | — | — | EP | claimed |
| US-20060116383-A1 | Integrin antagonists useful as anticancer agents | ALCATEL LUCENT (FR) | 2006-06-01 | — | — | US | claimed |
| WO-2006053342-A2 | INTEGRIN ANTAGONISTS USEFUL AS ANTICANCER AGENTS | OSI PHARMACEUTICALS, INC. (US) | 2006-05-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116383-A1 | Integrin antagonists useful as anticancer agents | ITGB5, ITGA5, ITGB1 | TMPRSS4 969/4885P2RX1 394/4885P2RX4 513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.